🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Christine McCluskey

Dana-Farber Cancer Institute

ORCID: 0000-0001-5610-8115
MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168
Top 100%
0DataRank
Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Papers

Driven by 6 papers — median percentile 0. Top paper: “Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial”.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Nature(2018)10.1038/s41586-018-0792-9
N/A
1.1DataRank · unranked
1412 citations

Jing Sun, Itay Tirosh, Nathan D. Mathewson, Shuqiang Li, Giacomo Oliveira +51 more

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2500
N/A
0.835DataRank · unranked
261 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort

Nature Communications(2024)10.1038/s41467-024-54326-7
N/A
0.730DataRank · unranked
37 citations

Lu Sun, Gilbert C. Youssef, Raymond Y. Huang, Gang Li, Jiyoon Kim +31 more

ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS

Neuro-Oncology(2018)10.1093/neuonc/noy148.027
N/A
0DataRank · unranked
0 citations

Itay Tirosh, Annabelle Anandappa, Jing Sun, Chang‐Jiun Wu, Evisa Gjini +21 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168
Top 100%
0DataRank
Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168.v1
Top 100%
0DataRank
Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more